文章摘要
氨基酸转运载体SLC1A5在胃癌组织中的表达及其临床病理学意义
The expression of SLC1A5 in gastric cancer and its relation with the clinicopathological features of gastric cancer
投稿时间:2018-12-21  修订日期:2018-12-21
DOI:
中文关键词: 胃癌  SLC1A5  诊断  预后
英文关键词: gastric cancer  SLC1A5  diagnosis  prognosis
基金项目:无锡市卫生计生科研面上项目(MS201720);无锡市重点学科(DXK002);无锡市院士工作站(CYR1705)
作者单位E-mail
陆健 无锡市第二人民医院 ljhaimen@163.com 
龚镭 江苏省无锡市第二人民医院 13961862526@163.com 
王小云   
张丽莉   
杨怡莎   
摘要点击次数: 141
全文下载次数: 0
中文摘要:
      目的:研究SLC1A5蛋白在胃癌组织中的表达情况,并探讨其与胃癌临床病理特征及预后的相关性。 方法:收集进展期胃癌组织及对应癌旁组织90例,应用免疫组化技术检测SLC1A5在上述组织中的表达情况,并统计分析其表达与胃癌临床病理特征及预后的关系。同时通过基因数据库分析SLC1A5在胃癌组织和癌旁组织中表达情况及其对胃癌患者预后的影响。 结果:与癌旁组织相比,胃癌组织中SLC1A5表达明显上调(P<0.0001)。数据库研究证实SLC1A5在胃癌组织中表达明显上调(GSE 65801, P =0.0046;GSE 63809,P<0.0001;GSE 27342,P=0.0147)。胃癌组织中SLC1A5高表达与肿瘤大小(P<0.05)、肿瘤浸润深度(P<0.01)、淋巴结转移(P<0.05)、TNM分期(P<0.05)和Ki-67(P<0.01)相关,而与年龄、性别、肿瘤位置及分化程度无关。胃癌中SLC1A5表达强度与预后相关,表达越高,预后越差(总体生存率,P=0.0131;无复发生存率,P=0.0293)。同时数据库分析也证实,SLC1A5高表达可明显缩短患者的总体生存期(GSE 14210,P=0.011;GSE 22377,P=0.0015),同时缩短患者的无进展生存期(GSE 14210,P=0.0095;GSE 22377,P=0.0012)。 结论:SLC1A5蛋白在胃癌组织中表达上调,SLC1A5表达与肿瘤大小、肿瘤浸润深度、淋巴结转移及TNM分期有关。SLC1A5高表达与胃癌患者预后不良有关。
英文摘要:
      Object:To observe the expression of SLC1A5 in GC and analyze its relation with the clinicopathological features and prognosis and of GC. Method: 90 cases of advanced gastric cancer tissues were selected as experiment group, and corresponding paracancerous tissues were showed as control group. Immunohistochemistry were used to observe the protein expression levels of SLC1A5 in two groups. The expression of SLC1A5 in 90 cases of advanced gastric cancer and its adjacent tissues was detected by immunohistochemistry. The relationship between the expression of SLC1A5 and clinicopathological features, as well as prognosis of gastric cancer was analyzed. By using gene database, we also analyzed the expression level of SLC1A5 in gastric cancer tissues and adjacent tissues, and its relation with prognosis of GC. Results: Compared to the control group, the expression level of SLC1A5 significantly increased in advanced GC (P<0.0001). Statistical analysis by using GSE database also confirmed that the expression level of SLC1A5 significantly increased in GC tissues compared to the paracancerous tissues (GSE 65801, P =0.0046; GSE 63809, P<0.0001; GSE 27342, P=0.0147). The expression level of SLC1A5 in gastric cancer tissues was correlated with tumor size (P<0.05), depth of invasion (P<0.01), lymph node metastasis (P<0.05), TNM stage (P<0.05) and Ki-67 index (P<0.01). It was not related to age, sex, tumor location and degree of differentiation. Overexpression of SLC1A5 in gastric cancer was associated with poor prognosis (overall survival rate, P = 0.0131; non-recurrence survival rate, P = 0.0293). Meanwhile, database analysis is also confirmed that higher expression level of SLC1A5 in GC is associated with poor prognosis, which can significantly shorten the overall survival time (GSE 14210, P=0.011, GSE 22377, P=0.0015), and the progression free survival time of GC patients (GSE 14210, P=0.0095; GSE 22377, P=0.0012). Conclusion:SLC1A5 protein expression in GC tissue increased, and the expression of SLC1A5 is associated with tumor size, depth of invasion, lymph node metastasis, TNM stage in advanced GC. High expression of SLC1A5 is associated with poor prognosis in patients with gastric cancer.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭